Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.

Honig, Lawrence S; Sabbagh, Marwan N; van Dyck, Christopher H; Sperling, Reisa A; Hersch, Steven; Matta, Andre; Giorgi, Luigi; Gee, Michelle; Kanekiyo, Michio; Li, David; Purcell, Derk; Dhadda, Shobha; Irizarry, Michael; Kramer, Lynn.

Afiliación

Honig LS; Columbia University Irving Medical Center, NYS Center of Excellence for Alzheimer's Disease, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Gertrude H. Sergievsky Center (PH19), & Department of Neurology, Columbia University Vagelos College of Physicians & Surgeons,
Sabbagh MN; Barrow Neurological Institute, Phoenix, AZ, 85013, USA.
van Dyck CH; Yale School of Medicine, New Haven, CT, USA.
Sperling RA; Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Hersch S; Eisai Inc., Nutley, NJ, USA.
Matta A; Eisai Inc., Nutley, NJ, USA.
Giorgi L; Eisai Co., Ltd, Hatfield, UK.
Gee M; Eisai Co., Ltd, Hatfield, UK.
Kanekiyo M; Eisai Inc., Nutley, NJ, USA.
Li D; Eisai Inc., Nutley, NJ, USA.
Purcell D; Clario, Philadelphia, PA, USA.
Dhadda S; Eisai Inc., Nutley, NJ, USA.
Irizarry M; Eisai Inc., Nutley, NJ, USA.
Kramer L; Eisai Inc., Nutley, NJ, USA.

Alzheimers Res Ther ; 16(1): 159, 2024 Jul 10.

Article en En | MEDLINE | ID: mdl-38987826

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Alzheimers Res Ther Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Alzheimers Res Ther Año: 2024 Tipo del documento: Article